Plain-English translation of NCT06821945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing olanzapine, a medication used to treat schizophrenia, to find the best way to start taking it. Researchers want to compare two different starting schedules—one that increases the dose gradually and one that uses a more conventional approach—to see which one works better and causes fewer side effects for patients.
People with schizophrenia sometimes need to start on lower doses of medication than usual, depending on their health. This trial exists to figure out the safest and most effective way to gradually introduce this medication for patients who need a gentler approach.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive the medication using one of two different starting schedules. Over the course of the trial, you would have multiple visits where researchers check how well the medication is working, monitor any side effects, and gradually adjust your dose according to your assigned schedule. The study involves 120 participants across multiple centers, and you would be monitored carefully to ensure your safety throughout the process.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
South Korea
Phase
Testing effectiveness
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment target
~120 participants
Started
May 2025
Primary completion
May 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shin-young Oh
Boryung Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.